- Patent Title: Pyrimidines as EGFR inhibitors and methods of treating disorders
-
Application No.: US15742113Application Date: 2016-07-20
-
Publication No.: US10550112B2Publication Date: 2020-02-04
- Inventor: Nathanael S. Gray , Jaebong Jang , Pasi Janne
- Applicant: Dana-Farber Cancer Institute, Inc.
- Applicant Address: US MA Boston
- Assignee: Dana-Farber Cancer Institute, Inc.
- Current Assignee: Dana-Farber Cancer Institute, Inc.
- Current Assignee Address: US MA Boston
- Agency: Burns & Levinson, LLP
- Agent Daniel W. Clarke
- International Application: PCT/US2016/043124 WO 20160720
- International Announcement: WO2017/015363 WO 20170126
- Main IPC: C07D413/14
- IPC: C07D413/14 ; C07D403/12 ; C07D401/14 ; C07D403/14 ; C07D409/14 ; A61P31/12
Abstract:
The application relates to a compound having Formula (I′): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
Public/Granted literature
- US20180194758A1 NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS Public/Granted day:2018-07-12
Information query
